Across TCGA pan-cancer cohorts, ATP6V1G1P1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of ATP6V1G1P1’s most consistent transcriptional readouts.
The strongest signal is observed in prostate adenocarcinoma (PRAD), where ATP6V1G1P1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types ATP6V1G1P1 is over-expressed in tumor.
PRAD and BRCA are the cancer types where ATP6V1G1P1 tumor–normal differential expression is most reproducible.